Sanofi Walks Away From Plavix Provincial Tender In China
This article was originally published in PharmAsia News
Executive Summary
Despite expected pricing pressure, the depth of cuts from China’s closely watched provincial tenders for newly added essential drugs still bring out surprises, and even walkaways, as reference pricing remains a threat.
You may also be interested in...
Spring Coming? EU Group Holds China To Fair Play Promises In Procurement
A major European business group in China is encouraged by recent signals of further policy reforms, but says in a new report it would like to see further progress on drug and device tenders, the lifting of indirect competition restrictions, and full implementation of the central push for a level playing field for foreign firms.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.